Sugi Predict

Sugi Predict / Compounds / SCHEMBL3433069

SCHEMBL3433069

SCHEMBL3433069

NC(=O)c1cccc(-c2ccccc2)c1N

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BCAT2 O15382 2/20 0.71
▸ IKBKB O14920 8/20 0.54
▸ CHUK O15111 5/20 0.54
▸ IKBKE Q14164 1/20 0.54
▸ PKMYT1 Q99640 1/20 0.54
▸ HNF4A P41235 1/20 0.52
▸ KEAP1 Q14145 1/20 0.49
▸ NFE2L2 Q16236 1/20 0.49
▸ NPC1 O15118 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ PARP1 P09874 3/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ KDM4E B2RXH2 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ MAPT P10636 1/20 0.45
▸ HPGD P15428 1/20 0.45
▸ TSHR P16473 1/20 0.45
▸ HSD17B10 Q99714 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1512152 0.92 BCAT2 (0.59) BCAT2IKBKBCHUKIKBKEPKMYT1
SCHEMBL3791160 0.87 BCAT2 (0.53) BCAT2IKBKBCHUKIKBKEPKMYT1
SCHEMBL4592875 0.86 BCAT2 (0.57) BCAT2IKBKBCHUKIKBKEPKMYT1
SCHEMBL758071 0.86 HNF4A (0.63) BCAT2IKBKBCHUKIKBKEPKMYT1
SCHEMBL1512155 0.86 BCAT2 (0.55) BCAT2IKBKBCHUKIKBKEPKMYT1
SCHEMBL29032707 0.85 BCAT2 (0.60) BCAT2IKBKBCHUKIKBKEPKMYT1
SCHEMBL3784805 0.84 PARP1 (0.50) BCAT2IKBKBCHUKIKBKEPKMYT1
SCHEMBL7143118 0.84 CHUK (0.61) BCAT2IKBKBCHUKIKBKEPKMYT1
SCHEMBL6590788 0.84 IKBKB (0.52) BCAT2IKBKBCHUKKEAP1NFE2L2
SCHEMBL28282551 0.84 BCAT2 (0.50) BCAT2IKBKBCHUKIKBKEPKMYT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114423741-B aryl-N-aryl derivatives for the treatment of RNA viral infections ABIVAX公司 2023-11-07 — — CN disclosed
CN-115925632-A Imidazole phenyl aminobenzamide compound with antitumor activity 江苏海洋大学 2023-04-07 — — CN disclosed
CN-115925632-A Imidazole phenyl aminobenzamide compound with antitumor activity 江苏海洋大学 2023-04-07 — — CN disclosed
CN-115925632-A Imidazole phenyl aminobenzamide compound with antitumor activity 江苏海洋大学 2023-04-07 — — CN disclosed
CN-114423741-A aryl-N-aryl derivatives for the treatment of RNA viral infections ABIVAX公司 2022-04-29 — — CN disclosed
CN-105732521-B A kind of preparation method of dihydroquinazoline ketone derivatives 华中科技大学 2017-12-29 — — CN disclosed
CN-102471335-B Azanebicyclic compound or salt thereof TAIHO PHARMACEUTICAL CO.,LTD. (JP) 2015-09-30 — — CN disclosed
CN-104710420-A Azabicyclo compound and salt thereof, medication and composition containing same, and application thereof TAIHO PHARMACEUTICAL CO LTD 2015-06-17 — — CN disclosed
CN-102300854-A Benzothiazole derivatives as anticancer agents — 2011-12-28 — — CN disclosed
CN-102065895-A Therapeutic combinations of anti-IGF-1R antibodies and other compounds BIOGEN IDEC INC 2011-05-18 — — CN disclosed
US-20060014747-A1 Ortho-substituted anthranilic acid amides and their use as pharmaceutical agents BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2006-01-19 — — US disclosed
CN-1237062-C Ortho-substituted anthranilic acid amides and their use as medicaments SCHERING AG (DE) 2006-01-18 — — CN disclosed
CN-1163475-C 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors ��ʲ 2004-08-25 — — CN disclosed
US-20040102441-A1 Ortho-substituted anthranilic acid amides and their use as medicaments BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2004-05-27 — — US disclosed
CN-1151133-C Anthranilic acid amides and the use thereof as medicaments ���ֹɷݹ�˾ 2004-05-26 — — CN disclosed
CN-1427837-A Ortho-substituted anthranilic acid amides and their use as medicaments SCHERING AG (DE) 2003-07-02 — — CN disclosed
CN-1350530-A Amide derivatives ASTRAZENECA AB (SE) 2002-05-22 — — CN disclosed
CN-1333698-A Combination chemotherapy WARNER LAMBERT CO (US) 2002-01-30 — — CN disclosed
CN-1325384-A Anthranilic acid amides and the use thereof as medicaments SCHERING AG (DE) 2001-12-05 — — CN disclosed
US-4602961-A MONOAZO BENZOTHIAZOLE DERIVATIVES CIBA-GEIGY CORPORATION (US) 1986-07-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014747-A1 Ortho-substituted anthranilic acid amides and their use as pharmaceutical agents VEGFA, TEK, OGFR BCAT2 1661/4885IKBKB 884/4885CHUK 510/4885
US-20040102441-A1 Ortho-substituted anthranilic acid amides and their use as medicaments TEK, VEGFA, ASPH BCAT2 618/4885IKBKB 1014/4885CHUK 599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.